1 story in the last 7 days
The latest asthma news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks asthma across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

AbbVie is acquiring an eczema and asthma drug developer for nearly $11 billion. The deal adds a late-stage pipeline asset to AbbVie's immunology portfolio. The acquisition targets a developer with treatments for inflammatory conditions.
Summaries by ByteBrief